|
1
|
Hussain S, Jha S, Berger E, Molander L, Sevastianova V, Sheybani Z, Espinosa AS, Elmahdy A, Al-Awar A, Kakaei Y, Kalani M, Zulfaj E, Nejat A, Jha A, Pylova T, Krasnikova M, Andersson EA, Omerovic E, Redfors B. Comparative Analysis of Plasma Protein Dynamics in Women with ST-Elevation Myocardial Infarction and Takotsubo Syndrome. Cells 2024; 13:1764. [PMID: 39513871 PMCID: PMC11545104 DOI: 10.3390/cells13211764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Revised: 10/08/2024] [Accepted: 10/23/2024] [Indexed: 11/16/2024] Open
Abstract
BACKGROUND ST-elevation myocardial infarction (STEMI) and Takotsubo syndrome (TS) are two distinct cardiac conditions that both result in sudden loss of cardiac dysfunction and that are difficult to distinguish clinically. This study compared plasma protein changes in 24 women with STEMI and 12 women with TS in the acute phase (days 0-3 post symptom onset) and the stabilization phase (days 7, 14, and 30) to examine the molecular differences between these conditions. METHODS Plasma proteins from STEMI and TS patients were extracted during the acute and stabilization phases and analyzed via quantitative proteomics. Differential expression and functional significance were assessed. Data are accessible on ProteomeXchange, ID PXD051367. RESULTS During the acute phase, STEMI patients showed higher levels of myocardial inflammation and tissue damage proteins compared to TS patients, along with reduced tissue repair and anti-inflammatory proteins. In the stabilization phase, STEMI patients exhibited ongoing inflammation and disrupted lipid metabolism. Notably, ADIPOQ was consistently downregulated in STEMI patients in both phases. When comparing the acute to the stabilization phase, STEMI patients showed increased inflammatory proteins and decreased structural proteins. Conversely, TS patients showed increased proteins involved in inflammation and the regulatory response to counter excessive inflammation. Consistent protein changes between the acute and stabilization phases in both conditions, such as SAA2, CRP, SAA1, LBP, FGL1, AGT, MAN1A1, APOA4, COMP, and PCOLCE, suggest shared underlying pathophysiological mechanisms. CONCLUSIONS This study presents protein changes in women with STEMI or TS and identifies ADIPOQ, SAA2, CRP, SAA1, LBP, FGL1, AGT, MAN1A1, APOA4, COMP, and PCOLCE as candidates for further exploration in both therapeutic and diagnostic contexts.
Collapse
Affiliation(s)
- Shafaat Hussain
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Sandeep Jha
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
- Department of Cardiology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
| | - Evelin Berger
- Proteomics Core Facility, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden;
| | - Linnea Molander
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Valentyna Sevastianova
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Zahra Sheybani
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Aaron Shekka Espinosa
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Ahmed Elmahdy
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Amin Al-Awar
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Yalda Kakaei
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Mana Kalani
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Ermir Zulfaj
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
| | - Amirali Nejat
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
| | - Abhishek Jha
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Tetiana Pylova
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Maryna Krasnikova
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Erik Axel Andersson
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
| | - Elmir Omerovic
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Department of Cardiology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
| | - Björn Redfors
- Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden; (S.J.); (L.M.); (V.S.); (Z.S.); (A.S.E.); (A.E.); (A.A.-A.); (Y.K.); (M.K.); (E.Z.); (A.N.); (A.J.); (T.P.); (M.K.); (E.A.A.); (E.O.); (B.R.)
- Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
- Department of Cardiology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
| |
Collapse
|
|
2
|
Shibata N, Ito T, Toyoda H, Tanaka A, Morita Y, Kanzaki Y, Watanabe N, Yoshioka N, Yasuda S, Morishima I. Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2024; 34:2115-2123. [PMID: 38664121 DOI: 10.1016/j.numecd.2024.03.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 02/23/2024] [Accepted: 03/20/2024] [Indexed: 08/06/2024]
Abstract
BACKGROUND AND AIMS Patients with nonalcoholic fatty liver disease (NAFLD) have a higher risk of cardiac events. However, although the severity of liver fibrosis is related to worsening prognosis in patients with NAFLD, it is unclear whether the noninvasive liver fibrosis score has a predictive value for cardiac events. METHODS AND RESULTS We evaluated 4071 patients with NAFLD diagnosed using ultrasonography. Liver fibrosis was assessed and divided into three groups based on the Fibrosis-4 (FIB4) index and NAFLD fibrosis score (NFS). The primary outcome of this study was major adverse cardiac events (MACE), including cardiac death, nonfatal myocardial infarction, and revascularization due to coronary artery disease. The median age of the evaluated patients was 61 (52-69) years, and 2201 (54.1%) were male. During the median follow-up period of 6.6 years, 179 (4.4%) patients experienced MACE. Kaplan-Meier survival analysis demonstrated that MACE increased progressively with the FIB4 index (log-rank, p < 0.001) and NFS (log-rank, p < 0.001). Multivariable analysis showed that the higher the FIB4 index, the higher the risk for MACE (low group as reference vs. intermediate group, hazard ratio [HR]: 1.860 [95% confidence interval (CI), 1.326-2.610; p < 0.001]; vs. high group, HR:3.325 [95% CI, 2.017-5.479; p < 0.001]), as well as NFS (low NFS group as reference vs. intermediate group, HR: 1.938 [95% CI, 1.391-2.699; p < 0.001]; vs. high group, HR: 3.492 [95% CI, 1.997-6.105; p < 0.001]). CONCLUSIONS The FIB4 index and NFS are associated with the probability of MACE in patients with NAFLD. CLINICAL TRIALS The study design was approved by the ethics review board of Ogaki Municipal Hospital (approval number: 20221124-12, registration date: November 28th, 2022). https://www.ogaki-mh.jp/chiken/kenkyu.html.
Collapse
Affiliation(s)
- Naoki Shibata
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Takanori Ito
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Hidenori Toyoda
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Akihito Tanaka
- Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yasuhiro Morita
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Yasunori Kanzaki
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Naoki Watanabe
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Naoki Yoshioka
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Satoshi Yasuda
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Itsuro Morishima
- Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.
| |
Collapse
|
|
3
|
Elahimanesh M, Shokri N, Mahdinia E, Mohammadi P, Parvaz N, Najafi M. Differential gene expression patterns in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction. Sci Rep 2024; 14:3424. [PMID: 38341440 PMCID: PMC10858964 DOI: 10.1038/s41598-024-54086-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Accepted: 02/08/2024] [Indexed: 02/12/2024] Open
Abstract
The ST-elevation Myocardial Infarction (STEMI) and Non-ST-elevation Myocardial Infarction (NSTEMI) might occur because of coronary artery stenosis. The gene biomarkers apply to the clinical diagnosis and therapeutic decisions in Myocardial Infarction. The aim of this study was to introduce, enrich and estimate timely the blood gene profiles based on the high-throughput data for the molecular distinction of STEMI and NSTEMI. The text mining data (50 genes) annotated with DisGeNET data (144 genes) were merged with the GEO gene expression data (5 datasets) using R software. Then, the STEMI and NSTEMI networks were primarily created using the STRING server, and improved using the Cytoscape software. The high-score genes were enriched using the KEGG signaling pathways and Gene Ontology (GO). Furthermore, the genes were categorized to determine the NSTEMI and STEMI gene profiles. The time cut-off points were identified statistically by monitoring the gene profiles up to 30 days after Myocardial Infarction (MI). The gene heatmaps were clearly created for the STEMI (high-fold genes 69, low-fold genes 45) and NSTEMI (high-fold genes 68, low-fold genes 36). The STEMI and NSTEMI networks suggested the high-score gene profiles. Furthermore, the gene enrichment suggested the different biological conditions for STEMI and NSTEMI. The time cut-off points for the NSTEMI (4 genes) and STEMI (13 genes) gene profiles were established up to three days after Myocardial Infarction. The study showed the different pathophysiologic conditions for STEMI and NSTEMI. Furthermore, the high-score gene profiles are suggested to measure up to 3 days after MI to distinguish the STEMI and NSTEMI.
Collapse
Affiliation(s)
- Mohammad Elahimanesh
- Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
| | - Nafiseh Shokri
- Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
| | - Elmira Mahdinia
- Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
| | - Payam Mohammadi
- Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
| | - Najmeh Parvaz
- Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
| | - Mohammad Najafi
- Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
|
6
|
Liang S, Li H, Shen X, Liu R. Increased serum adiponectin predicts improved coronary flow and clinical outcomes in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Clin Lab Anal 2019; 33:e22864. [PMID: 30779470 PMCID: PMC6595347 DOI: 10.1002/jcla.22864] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 01/27/2019] [Accepted: 01/30/2019] [Indexed: 12/22/2022] Open
Abstract
Background Previous studies suggested that adiponectin (APN) could ameliorate ischemia/reperfusion injury and endothelial dysfunction in patients with acute myocardial infarction. However, the relationship between serum APN level and coronary flow after primary percutaneous coronary intervention (PPCI) in patients with ST‐segment elevation myocardial infarction (STEMI) is unclear. Methods A total of 144 patients with STEMI treated by PPCI were enrolled and divided into two groups based on the mean serum APN level on admission. The data on coronary angiograms and laboratory examinations were collected and compared between groups. The incidence of major adverse cardiac events (MACE) was evaluated in all enrolled patients. Results The prevalence of Thrombolysis In Myocardial Infarction (TIMI) flow grade <3 after PPCI and corrected TIMI frame count were lower in the high‐APN group (P = 0.032 and P = 0.029, respectively). Logistic regression analysis demonstrated that APN was an independent negative predictor of poor coronary flow after PPCI (odds ratio = 0.72, 95% CI: 0.56‐0.93, P = 0.011). Kaplan‐Meier curves showed that a higher APN level correlated with a better MACE‐free survival rate, and multivariate Cox hazard regression analysis indicated that high APN was a significant negative predictor of MACE (hazard ratio = 0.54, 95% CI: 0.29‐1.00, P = 0.048). Conclusion Elevated serum levels of APN on admission are associated with improved myocardial blood flow and clinical outcomes in STEMI patients treated with PPCI.
Collapse
Affiliation(s)
- Siwen Liang
- Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Hongwei Li
- Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Xuhua Shen
- Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Ruifeng Liu
- Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| |
Collapse
|